A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain
- PMID: 20696525
- DOI: 10.1016/j.pain.2010.07.019
A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain
Abstract
Cannabinoids are analgesic in man, but their use is limited by their psychoactive properties. One way to avoid cannabinoid receptor subtype 1 (CB1R)-mediated central side-effects is to develop CB1R agonists with limited CNS penetration. Activation of peripheral CB1Rs has been proposed to be analgesic, but the relative contribution of peripheral CB1Rs to the analgesic effects of systemic cannabinoids remains unclear. Here we addressed this by exploring the analgesic properties and site of action of AZ11713908, a peripherally restricted CB1R agonist, in rodent pain models. Systemic administration of AZ11713908 produced robust efficacy in rat pain models, comparable to that produced by WIN 55, 212-2, a CNS-penetrant, mixed CB1R and CB2R agonist, but AZ11713908 generated fewer CNS side-effects than WIN 55, 212-in a rat Irwin test. Since AZ11713908 is also a CB2R inverse agonist in rat and a partial CB2R agonist in mouse, we tested the specificity of the effects in CB1R and CB2R knock-out (KO) mice. Analgesic effects produced by AZ11713908 in wild-type mice with Freund's complete adjuvant-induced inflammation of the tail were completely absent in CB1R KO mice, but fully preserved in CB2R KO mice. An in vivo electrophysiological assay showed that the major site of action of AZ11713908 was peripheral. Similarly, intraplantar AZ11713908 was also sufficient to induce robust analgesia. These results demonstrate that systemic administration of AZ11713908, produced robust analgesia in rodent pain models via peripheral CB1R. Peripherally restricted CB1R agonists provide an interesting novel approach to analgesic therapy for chronic pain.
Copyright © 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Role of primary sensory neurone cannabinoid type-1 receptors in pain and the analgesic effects of the peripherally acting agonist CB-13 in mice.Br J Anaesth. 2022 Jan;128(1):159-173. doi: 10.1016/j.bja.2021.10.020. Epub 2021 Nov 26. Br J Anaesth. 2022. PMID: 34844727 Free PMC article.
-
Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice.J Pharmacol Exp Ther. 2017 Aug;362(2):296-305. doi: 10.1124/jpet.117.241901. Epub 2017 Jun 7. J Pharmacol Exp Ther. 2017. PMID: 28592614 Free PMC article.
-
A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.Eur J Pharmacol. 2005 Dec 28;528(1-3):65-72. doi: 10.1016/j.ejphar.2005.10.043. Epub 2005 Nov 28. Eur J Pharmacol. 2005. PMID: 16316650
-
Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.Expert Opin Investig Drugs. 2014 Aug;23(8):1123-40. doi: 10.1517/13543784.2014.918603. Epub 2014 May 16. Expert Opin Investig Drugs. 2014. PMID: 24836296 Review.
-
Cannabinoids and Pain: Sites and Mechanisms of Action.Adv Pharmacol. 2017;80:437-475. doi: 10.1016/bs.apha.2017.05.003. Epub 2017 Jun 20. Adv Pharmacol. 2017. PMID: 28826543 Review.
Cited by
-
Turning Down the Thermostat: Modulating the Endocannabinoid System in Ocular Inflammation and Pain.Front Pharmacol. 2016 Sep 15;7:304. doi: 10.3389/fphar.2016.00304. eCollection 2016. Front Pharmacol. 2016. PMID: 27695415 Free PMC article. Review.
-
The endocannabinoid system in canine Steroid-Responsive Meningitis-Arteritis and Intraspinal Spirocercosis.PLoS One. 2018 Feb 6;13(2):e0187197. doi: 10.1371/journal.pone.0187197. eCollection 2018. PLoS One. 2018. PMID: 29408878 Free PMC article.
-
Comparative antinociceptive effect of arachidonylcyclopropylamide, a cannabinoid 1 receptor agonist & lignocaine, a local anaesthetic agent, following direct intrawound administration in rats.Indian J Med Res. 2016 Nov;144(5):730-740. doi: 10.4103/ijmr.IJMR_1402_15. Indian J Med Res. 2016. PMID: 28361827 Free PMC article.
-
Therapeutic Agents for the Treatment of Temporomandibular Joint Disorders: Progress and Perspective.Front Pharmacol. 2021 Jan 29;11:596099. doi: 10.3389/fphar.2020.596099. eCollection 2020. Front Pharmacol. 2021. PMID: 33584275 Free PMC article. Review.
-
Role of primary sensory neurone cannabinoid type-1 receptors in pain and the analgesic effects of the peripherally acting agonist CB-13 in mice.Br J Anaesth. 2022 Jan;128(1):159-173. doi: 10.1016/j.bja.2021.10.020. Epub 2021 Nov 26. Br J Anaesth. 2022. PMID: 34844727 Free PMC article.
References
-
- Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci. 2007;10:870-879.
-
- Akerman S, Kaube H, Goadsby PJ. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004;309:56-63.
-
- Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112:299-306.
-
- Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55, 212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol. 2001;133:586-594.
-
- Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: a novel cannabinoid produces analgesia without a “high”. Life Sci. 2004;75:1513-1522.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous